A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

Clinical trial NCT05169489 · TERMINATED

Trial details

NCT number: NCT05169489
Sponsor: Regeneron Pharmaceuticals
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Diffuse Large B Cell Lymphoma (DLBCL)

Start date: 2022-01-24
Primary completion: 2025-09-19
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.